Nov 3 Notizia

Notizia

AstraZeneca and Incyte are about to enter into Clinical Trial Collaboration in Early Lung Cancer

  • The exclusive collaboration for the study population allows the two companies to conduct a Phase 3 trial. Aim of this study is to evaluate patients with locally-advanced (Stage III), unresectable non-small cell lung cancer (NSCLC), whose disease has not progressed following platinum-based chemotherapy concurrent with radiation therapy (CRT).

Tocagen’s combo therapy enters directly into phase 3 trials after getting approval from FDA

  • Tocagen is moving directly into a phase 3 trial with its combo therapy Toca 511 and Toca FC gene therapy in cancer and thus needs more patients. To facilitate the process FDA has provided a $2 million orphan drug grant payable over four years.

FDA warns companies marketing unverified products, derived from marijuana, claiming cancer treatment or cure

  • Under the U.S. Food and Drug Administration’s ongoing efforts to protect consumers from health fraud. The agency has recently issued warning letters to four companies. Action is taken against the companies illegally selling marijuana products online claiming to prevent, diagnose, treat, or cure cancer without any evidence to support the same.

FDA about to Revoke Claims regarding Heart Health benefits of Soy

  • In a recent statement Susan Mayne, director of the Center for Food Safety and Applied Nutrition at the FDA has said that, the relationship between soy protein and heart health does not meet the rigorous standard for an FDA-authorized health claim.

 

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.